ArticleClinical epigenetics2024
Technical variability across the 450K, EPICv1, and EPICv2 DNA methylation arrays: lessons learned for clinical and longitudinal studies.
Article in Clinical epigenetics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- The aging epigenome: integrative analyses reveal intersection with Alzheimer's disease.GeroScience · 2026Pooled it
- Exercise and nutrition as epigenetic regulators of gene expression: an exploratory scoping review with bibliometric analysis.Frontiers in nutrition · 2026Pooled it
- Epigenetic age deceleration reflects exercise-induced cardiorespiratory fitness improvements.GeroScience · 2026Article
- Epigenetic Alterations in Meningiomas-A Review.Biomedicines · 2026Review
- Article
- Longitudinal Changes in Inflammation-Related Methylation Risk Score for C-Reactive Protein Among People with HIV.Epigenomes · 2026Article
- Biological Versus Technical Reliability of Epigenetic Clocks and Implications for Disease Prognosis and Intervention Response.Aging cell · 2026Article
- Peripheral blood mononuclear cell DNA methylation signatures guide surgical decision-making in indeterminate pulmonary nodules.Communications medicine · 2026Article
- Physiological health Age (PhysAge): a novel multi-system molecular timepiece predicts health and mortality in older adults.GeroScience · 2026Article
- A comparison of differential DNA methylation analysis methods for continuous outcomes: implications for epigenetic studies.Epigenomics · 2026Article
- Recurrent single-CpG methylation differences and incomplete segregation in familial type 1 diabetes.Frontiers in immunology · 2026Article
- Gestational phthalate levels and biomarkers of aging in infants and children from New York City.Environmental research · 2025Article
- TranslAGE: A Comprehensive Platform for Systematic Validation of Epigenetic Aging Biomarkers.bioRxiv : the preprint server for biology · 2025Article
- Cell-Free DNA Bisulfite Sequencing Reveals Epithelial-Mesenchymal Transition Signatures for Breast Cancer.International journal of molecular sciences · 2025Article
- Placental DNA methylation key topics: sex- and cell-type specificity, mediation, multi-omics, and biomarker discovery.Epigenomics · 2025Review
- Accounting for differences between Infinium MethylationEPIC v2 and v1 in DNA methylation-based tools.Life science alliance · 2025Article
- Epigenetic clocks and DNA methylation biomarkers of brain health and disease.Nature reviews. Neurology · 2025Review
- Accounting for differences between Infinium MethylationEPIC v2 and v1 in DNA methylation-based tools.bioRxiv : the preprint server for biology · 2025Article
- DNAm age differences between infinium methylationEPICv1 vs EPICv2 in buffy coat, PBMC, and saliva samples.Communications biology · 2025Article
- Unlocking the future of complex human diseases prediction: multi-omics risk score breakthrough.Frontiers in bioinformatics · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
DNA methylation (DNAm) is the most commonly measured epigenetic mechanism in human populations, with most studies using Illumina arrays to assess DNAm levels. In 2023, Illumina updated their DNAm arrays to the EPIC version 2 (EPICv2), building on prior iterations, namely the EPIC version 1 (EPICv1) and 450K arrays. Whether DNAm measurements are stable across these three generations of arrays has yet not been investigated, limiting the ability of researchers-especially those with longitudinal data-to compare and replicate results across arrays. Here, we present results from a study of 30 child participants (15 male; 15 female) from the Drakenstein Child Health Study, who had DNAm measured on all three of the latest arrays: 450K, EPICv1, and EPICv2. Using these data, we created an annotation of probe quality across arrays, which includes the intraclass correlations, interquartile ranges, correlations, and array bias (i.e., the extent to which DNAm levels were explained by array type) of all CpGs. We also present results from an analysis of sex differences, where we found that CpGs with lower replicability across arrays had higher array-based variance, suggesting this variance metric help guide replication efforts. We also showed that epigenetic age estimates across arrays were more stable when using the principal component versions of epigenetic clocks. Ultimately, this collection of results provides a framework for investigating the replicability and longitudinal stability of epigenetic changes across multiple versions of Illumina DNAm arrays.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.